➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
AstraZeneca
Medtronic
Johnson and Johnson
Colorcon

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

MECLIZINE HYDROCHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Meclizine Hydrochloride patents expire, and what generic alternatives are available?

Meclizine Hydrochloride is a drug marketed by Ivax Sub Teva Pharms, Nexgen Pharma Inc, Pliva, Abc Holding, Amneal Pharms, Anabolic, Ani Pharms Inc, Aurex, Bundy, Epic Pharma Llc, Indicus Pharma, Invatech, Jubilant Cadista, Kv Pharm, Mylan Pharms Inc, Par Pharm, Rising, Sandoz, Superpharm, UDL, Vangard, Watson Labs, and Zydus. and is included in thirty-five NDAs.

The generic ingredient in MECLIZINE HYDROCHLORIDE is meclizine hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the meclizine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Meclizine Hydrochloride

A generic version of MECLIZINE HYDROCHLORIDE was approved as meclizine hydrochloride by INVATECH on May 22nd, 1989.

  Start Trial

Drug patent expirations by year for MECLIZINE HYDROCHLORIDE
Recent Clinical Trials for MECLIZINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospital Federal de BonsucessoPhase 4
Yvonne SadaPhase 1
Medical Corps, Israel Defense ForcePhase 4

See all MECLIZINE HYDROCHLORIDE clinical trials

Pharmacology for MECLIZINE HYDROCHLORIDE
Drug ClassAntiemetic
Physiological EffectEmesis Suppression
Medical Subject Heading (MeSH) Categories for MECLIZINE HYDROCHLORIDE

US Patents and Regulatory Information for MECLIZINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Udl MECLIZINE HYDROCHLORIDE meclizine hydrochloride TABLET;ORAL 088257-001 Jun 13, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Mylan Pharms Inc MECLIZINE HYDROCHLORIDE meclizine hydrochloride TABLET;ORAL 202640-003 Sep 17, 2012 DISCN No No   Start Trial   Start Trial   Start Trial
Zydus MECLIZINE HYDROCHLORIDE meclizine hydrochloride TABLET;ORAL 213957-001 Jun 23, 2020 AA RX No No   Start Trial   Start Trial   Start Trial
Kv Pharm MECLIZINE HYDROCHLORIDE meclizine hydrochloride TABLET;ORAL 085524-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Medtronic
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.